Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 2;25(5):184-187.
doi: 10.5152/ThoracResPract.2024.23054.

Clinical Course of Coronavirus disease 2019 C-19 in Patients with Bronchiectasis

Ebru Çakır Edis  1 , Aykut Çilli  2 , Deniz Kızılırmak  3 , Ayşın Şakar Coşkun  3 , Abdullah Sayıner  4 , Sedat Çiçek  2 , İnci Gülmez  5 , Meltem Çoban Ağca  6 , Benan Çağlayan  7 , Neslihan Özçelik  8 , Nurdan Köktürk  9 , Birsen Ocaklı  6 , Eyüp Sabri Uçan  10 ; TEBVEB researchers
Collaborators, Affiliations

Clinical Course of Coronavirus disease 2019 C-19 in Patients with Bronchiectasis

Ebru Çakır Edis et al. Thorac Res Pract. .

Abstract

Objective: Coronavirus disease 2019 (COVID-19) has affected the whole world and caused the death of more than 6 million people. The disease has been observed to have a more severe course in patients with chronic lung diseases. There are limited data regarding COVID-19 in patients with bronchiectasis. The aim of this article is to investigate the course of COVID-19 and factors affecting the clinical outcome in patients with bronchiectasis.

Material and methods: This study was conducted using the Turkish Adult Bronchiectasis Database (TEBVEB) to which 25 centers in Türkiye contributed between March 2019 and January 2022. The database consisted of 1035 patients, and COVID-19-related data were recorded for 606 patients.

Results: One hundred nineteen (19.6%) of the bronchiectasis patients (64 female, mean age 57.3 ± 13.9) had COVID-19. Patients with bronchiectasis who developed COVID-19 more frequently had other comorbidities (P = .034). They also more frequently had cystic bronchiectasis (P = .009) and their Bronchiectasis Severity Index was significantly higher (P = .019). Eighty-two (68.9%) of the patients who had COVID-19 were followed up in the outpatient clinic, 27 (22.7%) in the inpatient ward and 10 (8.4%) patients in the intensive care unit. There tended to be a higher percentage of males among patients admitted to the hospital (P = .073); similarly, the mean age of the patients admitted to the hospital was also higher (60.8 vs 55.8 years for the outpatients), but these differences did not reach statistical significance (P = .071).

Conclusion: In conclusion, this study showed that severe bronchiectasis, presence of cystic bronchiectasis and worse Bronchiectasis Severity Index are associated with the development of COVID-19, but not with the severity of infection.

Keywords: COVID-19; bronchiectasis; disease severity.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests: The authors have no conflicts of interest to declare.

Figures

Figure 1.
Figure 1.
Consort diagram.
See this image and copyright information in PMC

References

    1. Available at: www.covid19.who.int. Date of Access: 18.9.2022.
    1. Ejaz H, Alsrhani A, Zafar A, et al. COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health. 2020;13(12):1833 1839. ( 10.1016/j.jiph.2020.07.014) - DOI - PMC - PubMed
    1. Çakır Edis E. Chronic pulmonary diseases and COVID-19. Turk Thorac J. 2020;21(5):345 349. ( 10.5152/TurkThoracJ.2020.20091) - DOI - PMC - PubMed
    1. Leung JM, Niikura M, Yang CWT, Sin DD. COVID-19 and COPD. Eur Respir J. 2020;56(2):2002108. ( 10.1183/13993003.02108-2020) - DOI - PMC - PubMed
    1. Sheikh D, Tripathi N, Chandler TR, et al. Clinical outcomes in patients with COPD hospitalized with SARS-CoV-2 versus non-SARS-CoV-2 community-acquired pneumonia. Respir Med. 2022;191:106714. ( 10.1016/j.rmed.2021.106714) - DOI - PMC - PubMed

LinkOut - more resources